Full-Time

Director – Privacy Counsel

Confirmed live in the last 24 hours

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceuticals for serious diseases

Compensation Overview

$202k - $336.6k/yr

Senior, Expert

Tarrytown, NY, USA

This role is based at our Sleepy Hollow, NY location (4 days a week) and is not open to hybrid or fully remote assignments.

Category
Legal
Risk & Compliance
Legal & Compliance
Requirements
  • JD and licensed to practice law in New York (or eligible for licensure as a registered in-house counsel)
  • At least 7 years of legal experience at a law firm and/or in-house
  • At least 3 years of experience in privacy
  • Strong knowledge of local and global privacy laws and their application to the pharmaceutical/biotechnology industry
  • Deep understanding of privacy risks associated with ad tech and emerging technologies
  • Excellent relationship building skills
  • Demonstrated ability to work collaboratively and with all levels of the workforce
  • Exceptional oral, written, and presentation communication skills
  • High level of business acumen, influencing skills and ability to drive change
Responsibilities
  • Providing advice and counseling on a wide range of privacy and related issues such as advising on sensitive data, digital advertising, and use of emerging technologies/AI
  • Strategically assess potential privacy risks on new projects, including risk-mitigation counseling and advising on appropriate controls
  • Monitoring emerging regulations and supporting the operationalization of compliance with evolving laws
  • Upkeep and development of internal policies, procedures, and guidance documents; educating business clients through training and awareness programs; Improving and counseling on privacy program operations
  • Leading Regeneron’s Privacy Steward Council to drive initiatives that enhance data privacy across the organization
  • Collaborating with our Government Affairs division on opportunities to influence legislation
  • Assisting contracting teams in drafting, maintaining, and negotiating data processing agreements
  • Participating in industry group meetings to stay updated on best practices and emerging trends
Desired Qualifications
  • Biotechnology, pharmaceutical or related life science experience is strongly preferred
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often working with academic institutions and other pharmaceutical companies to enhance its efforts. Unlike many competitors, Regeneron focuses on both research and commercialization, generating revenue through the sale of its approved medicines and partnerships for co-development. The goal of Regeneron is to improve patient outcomes by providing effective treatments and ensuring they meet safety standards.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Regeneron's acquisition of 23andMe enhances its consumer genomics capabilities.
  • Dupixent's success in phase 4 trials strengthens Regeneron's position in respiratory biologics.
  • Investment in Alnylam Pharmaceuticals indicates strategic interest in RNA interference technology.

What critics are saying

  • Regeneron's acquisition of 23andMe may face regulatory and privacy challenges.
  • Failure of AERIFY-2 study could impact investor confidence in COPD treatments.
  • Intensifying competition in biologics market pressures Regeneron to innovate continuously.

What makes Regeneron Pharmaceuticals unique

  • Regeneron excels in developing life-transforming medicines for serious diseases.
  • The company leverages proprietary technologies for innovative drug discovery.
  • Regeneron's strategic partnerships enhance its research and development capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

PharmiWeb
Jun 16th, 2025
Eaaci: Dupixent Demonstrated Superiority Over Xolair (Omalizumab) In Chronic Rhinosinusitis With Nasal Polyps In Patients With Coexisting Asthma In First-Ever Presented Phase 4 Head-To-Head Respiratory Study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpointsDupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp size and sense of smell in CRSwNP, and lung function and disease control in asthma, with rapid improvements seen as early as 4 weeksResults reinforce the efficacy of Dupixent in treating both upper and lower respiratory diseases by targeting IL-4 and IL-13, two key drivers of type 2 inflammation Paris and Tarrytown, NY, June 15, 2025. Sanofi and Regeneron Pharmaceuticals, Inc. today presented positive results from the EVEREST phase 4 study of adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. In the study, Dupixent (dupilumab) outperformed Xolair (omalizumab) on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints. The data are from the first-ever presented head-to-head respiratory study with biologic medicines and were shared today in a late-breaking oral presentation at the 2025 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, Glasgow, UK. Eugenio De Corso, MD, PhD ENT Specialist, Otolaryngology, Head and Neck Surgery, Rhinology, A

PharmiWeb
Jun 2nd, 2025
Itepekimab Met The Primary Endpoint In One Of Two Copd Phase 3 Studies

Itepekimab met the primary endpoint in one of two COPD phase 3 studies. AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit. AERIFY-2 study, a second Phase 3 study, did not meet the primary endpoint despite a benefit seen earlier in the study

MarketBeat
Jun 1st, 2025
Summit Global Investments Invests $849,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Regeneron Pharmaceuticals Inc. purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $1,045,822,000.

CNBC
May 27th, 2025
23Andme To Delist From Nasdaq, Deregister With Sec

A sign is posted in front of the 23andMe headquarters in Sunnyvale, California, on Feb. 1, 2024.Justin Sullivan | Getty Images23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, according to a release. The move comes after Regeneron Pharmaceuticals said earlier this month that it will acquire "substantially all" of 23andMe's assets for $256 million. The drugmaker came out on top following a bankruptcy auction for 23andMe, a once high-flying genetic testing company that filed for for Chapter 11 bankruptcy protection in March.This is breaking news. Please refresh for updates

Pharmaceutical Technology
May 20th, 2025
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care

At the American Thoracic Society (ATS) 2025 Congress on 19 May, Sanofi and Regeneron announced the launch of a new Phase IIIb/IV clinical trial, AIM4, during an evening industry symposium.